Our ambition is to follow the science to discover, develop and deliver life-changing treatments that transform outcomes and increase the potential for cures.

We are leading a revolution in oncology to redefine cancer care.

Our ambition is to transform care for billions of people living with chronic diseases and deliver long-lasting immunity.

We are working to intervene earlier to protect vital organs, slow or reverse disease progression, and achieve remission for often degenerative, debilitating and life-threatening conditions, so many more people can live better, healthier lives.

Our mission remains to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines as well as supportive technologies and healthcare services.
 

As we expand the reach of our medicines, our growing pipeline of investigational molecules represents continued innovation on behalf of rare disease patients.

Building diverse talent and critical capabilities, and creating a culture of high performance.

Achievements in 2023:

76%

of employees stated they believe AstraZeneca performs as an enterprise team.

Ensuring our employees, managers and teams have the potential to develop and grow.

Achievements in 2023:

88%

of employees stated they believe we are building a culture of lifelong learning and development.

Focusing on delivering our inclusion and diversity strategy, and learning and development programmes.

Achievements in 2023:

50.1%

of our senior roles are filled by women.

More than 10,000 rare diseases are estimated to exist today, but fewer than 10% have approved treatment options. Rare disease community members face many unique challenges in pursuing equitable access to healthcare. We believe people with rare diseases deserve the same attention and investment to find and access therapies as anyone else. As we expand the geographies where our rare disease medicines are available, we continue to build relationships with patient communities early in our development programmes to better understand their needs.

The PHSSR is a non-profit, multisector, global collaboration with a unified goal of building more sustainable and resilient health systems, active in more than 30 countries. In 2023, PHSSR published its second Summary Report with insights from 18 countries, and launched research on seven new Asia-Pacific countries. PHSSR also established an EU expert advisory group, to support EU policymakers in improving policies on prevention and early detection of NCDs.

Our Healthy Heart Africa programme is committed to reducing hypertension and the burden of CV disease, aiming to reach 10 million people with elevated blood pressure across Africa by 2025. We work with local and global partners to raise awareness and offer training, screening and reduced cost treatment, where applicable. In 2023, the programme launched in eight of 10 planned grant countries, in addition to the existing nine countries of operation.

The multi award-winning Young Health Programme (YHP) aims to empower young people to make more informed choices about their health and catalyse a global, youth-led advocacy movement, supported by community programmes and research. It helps to develop young leaders and is focused on vulnerable and under-resourced communities in 40 countries. Through partnerships with more than 50 non-profit partners around the world, including UNICEF, the YHP promotes health literacy and policy action. In 2023, YHP won the Better Society Award for Partnership with an International Charity together with UNICEF.